BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33270606)

  • 21. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
    Brender C; Nielsen M; Kaltoft K; Mikkelsen G; Zhang Q; Wasik M; Billestrup N; Odum N
    Blood; 2001 Feb; 97(4):1056-62. PubMed ID: 11159537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
    Reddy SA
    Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
    Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
    J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.
    Kamstrup MR; Gjerdrum LM; Biskup E; Lauenborg BT; Ralfkiaer E; Woetmann A; Ødum N; Gniadecki R
    Blood; 2010 Oct; 116(14):2504-12. PubMed ID: 20538790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
    J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma.
    Peru S; Prochazkova-Carlotti M; Cherrier F; Velazquez J; Richard E; Idrissi Y; Cappellen D; Azzi-Martin L; Pham-Ledard A; Beylot-Barry M; Merlio JP; Poglio S
    J Invest Dermatol; 2022 Dec; 142(12):3243-3252.e10. PubMed ID: 35850209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
    Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
    Front Immunol; 2020; 11():579894. PubMed ID: 33072126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
    Bosisio FM; Cerroni L
    Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.
    Durgin JS; Weiner DM; Wysocka M; Rook AH
    J Am Acad Dermatol; 2021 Mar; 84(3):587-595. PubMed ID: 33352267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pentostatin treatment of cutaneous T-cell lymphoma.
    Dearden C; Matutes E; Catovsky D
    Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):37-40. PubMed ID: 10887643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A role for SATB1, a nuclear matrix association region-binding protein, in the development of CD8SP thymocytes and peripheral T lymphocytes.
    Nie H; Maika SD; Tucker PW; Gottlieb PD
    J Immunol; 2005 Apr; 174(8):4745-52. PubMed ID: 15814699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SATB1-dependent mitochondrial ROS production controls TCR signaling in CD4 T cells.
    Kuwabara T; Ishikawa F; Ikeda M; Ide T; Kohwi-Shigematsu T; Tanaka Y; Kondo M
    Life Sci Alliance; 2021 Nov; 4(11):. PubMed ID: 34583974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
    Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
    Huang Y; Su MW; Jiang X; Zhou Y
    Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
    Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
    J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SATB1 Is a Pivotal Epigenetic Biomarker in Cutaneous T-Cell Lymphomas.
    Poglio S; Merlio JP
    J Invest Dermatol; 2018 Aug; 138(8):1694-1696. PubMed ID: 30032787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
    Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
    Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.
    Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Lenz J; Speuser P; Erdmann S; Abuzahra F; Bowman E; Roszkiewicz J; Bieber T; Tüting T
    Br J Dermatol; 2005 Feb; 152(2):258-64. PubMed ID: 15727636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.